Life Science Insights

$380 billion is spent annually on musculoskeletal care in the United States — more than cancer, diabetes, and cardiac care combined. And 90% of patients don't follow their plan of care. Physical therapy has an adherence problem, and the model built around three in-clinic visits per week isn't solving it. In this episode, Abby McInturf, co-founder of Band Connect, joins Dan Mazzucco to talk...

During a feasibility study at MIT, patients walked on a robotic treadmill that removed the floor during the swing phase of gait. The result was simple and striking: people just walked better. One patient said, "I wish I could take it outside the lab." That sentence became a company. In this episode, Cadense co-founders Tyler Susko and Johannes Sauer, join Dan Mazzucco to talk about translating a d...

After sitting through what he calls his "thousandth demo day," Heath Naquin walked away convinced that the entire model was broken. Founders were being polished for investors rather than prepared for the real work of building a company. In this episode, Heath Naquin, VP of Government and Capital Engagement at the University City Science Center in Philadelphia, joins Dan Mazzucco to unpack the phil...

Dan yaps about his guests from Season 2 and introduces the theme for Season 3. This is not a full episode, but it is worth investing the eight minutes if you want to understand the whole season. Theme Music: Prelude , composed and performed by Benjamin Mazzucco, © 2026. Used with permission.

From October 2025 through April 2026, the SBIR program went dark. Now that it's back, what is different? In this episode, Jerry Hollister, Co-Owner of BBCetc, joins Dan Mazzucco to pull back the curtain on the SBIR reauthorization fight, including the political dynamics that delayed it for months, the new foreign influence provisions now written into law, and the strategic breakthrough authori...

Getting FDA clearance is not a business goal. It is a milestone on the way to one. The goal is revenue in year one, year two, year three — and if a startup's pitch deck doesn't show how reimbursement dynamics support that revenue, sophisticated investors will notice before founders do. In this episode, Erik Harris, founder of Market Access Solved, joins Dan Mazzucco to demystify the market...

NIH-funded researchers are brilliant scientists, but most are complete beginners when it comes to reimbursement strategy, design history files, and what the FDA actually cares about. By the time they realize it, they're months from a clinical study with no quality management system and a consultant asking, "Where's your design history file?" In this episode, Andrew J. DiMeo Sr., Ph. D., business a...

What happens when surgeons casually mention they're not seeing infections at expected rates, and a materials scientist realizes his ceramic spine implants might be doing something no one anticipated? In this episode, SINTX Technologies Chief Technology Officer Ryan Bock joins Dan Mazzucco to talk about the 17-year journey from research scientist to CTO. They discuss the serendipitous discovery...

Most founders think they need money. What they really need is someone who can tell them where their assumptions are wrong before they scale the wrong solution. In this episode, Mohit Prajapati, Chief Innovation Officer at Rift Innovation Studio, joins Dan Mazzucco to discuss the realities of bringing orthopedic and spine technologies from concept to commercialization. They explore stage-fit matchi...

Some people ask AI to write an SOP and are told to eat a few small rocks per day. Spencer Jones uploads 20 documents, writes a 15-minute prompt, and has the model interview him with 40 questions before it generates anything. In this episode, XO Medtech founder Spencer Jones joins Dan Mazzucco to talk about leveraging AI tools for medical device development. They discuss giving AI adequate context...

After an injury turned her away from the practice of medicine, Cellia Habita built Europe's largest genetic database for diabetes on her way to two decades of global biotech leadership. In this episode, "the Iron CMO" Cellia Habita joins Dan Mazzucco to talk about transitioning from academic medicine to biotech executive roles. They discuss why fractional CMOs fill a critical gap in early-stage co...

Sudden cardiac arrest kills 300,000 Americans each year. The standard treatment—manual chest compressions—hasn't meaningfully changed in 60 years and achieves less than 10% survival in most communities. In this episode, CPR Therapeutics founder and CEO Norman Paradis joins Dan Mazzucco to talk about developing the first multimodal automated CPR system. They discuss why emergency medicine gets...

Note: Dan's opening statement that this was the "last" episode in the season was just wrong. This interview was so good that it had to jump the queue. A physician treating patients all day sees exactly what devices and treatments are needed. An AI engineer two floors up could solve that problem in an afternoon. The question is: how do you get them in the same building? In this episod...

A family tragedy exposes the massive gap between how well we fund cardiovascular disease versus conditions that affect one in three women; an entrepreneur decides to build the missing solution. In this episode, Avana Health CEO and Co-Founder Peter Pacult joins Dan Mazzucco to talk about transforming personal loss into clinical innovation — navigating the underfunding crisis in women's health,...

What happens when a marine biologist-turned recruiter teaches herself to code and ends up building FDA-regulated medical devices — all through the power of being "really nosy" about how teams work? In this episode, TechSlice CEO Juliana Buonanno joins Dan Mazzucco to talk about navigating the intersection of software development and medical device regulation — from her unconventional pat...

Ann's passion lies in forging genuine connections to cultivate collaboration and unlock collective potential, driven by a desire to make a positive impact.

What happens when a deeply personal experience exposes a blind spot in women’s health and a team of entrepreneurs decides to build the device that should have existed all along? In this episode, CleoCare co-founder Frederico Stock joins Dan Mazzucco to talk about turning real-world unmet need into a clinically meaningful product — navigating validation, usability, population risk, and med-device d...

Dan Mazzucco summarizes Season 1 of Life Science Insights and provides some teasers for Season 2.

Is your science truly investable, or just interesting? Learn how early development decisions determine whether academic science can realistically become a drug, and how industry evaluates translatability long before the clinic. This episode helps you understand what it really takes to turn promising academic science into a viable drug program. Dr. Vijayakumar explains how early development decisio...

Know when to spin out your technology. This conversation helps academic innovators decide whether (and when) spinning out a company is the right move. Dr. Riley shares a practical framework for assessing commercialization readiness, beyond publications and grant success. You’ll learn how timing, team composition, and institutional context affect outcomes, and why spinning out too early can be as r...

Entrepreneurship without the mythology. An honest look at what it takes to build a medtech company, from customer discovery to leadership realities beyond the technology. This episode gives an honest look at what it actually means to build and lead a medtech company. Eric Sugalski draws on experience as a repeat founder to explain the realities behind product development, customer discovery, and o...

Design discipline is your competitive advantage. Discover how voice-of-customer insights and design controls enable strong science to become products that regulators clear and clinicians adopt. This episode explains why many medical products fail despite strong science, and how structured design thinking can dramatically improve outcomes. John Crombie shows how voice-of-customer insights and desig...

Investors fund programs with a clear path to launch. Understand why manufacturing and safety strategy matter early—and how CMC and tox shape investor confidence and program value. This episode demystifies CMC and toxicology—and explains why they matter far earlier than most founders expect. Dr. Silvon shows how manufacturing and safety planning shape investor confidence, regulatory credibility, an...

Regulation doesn’t have to be a black box. Learn how and when to engage FDA, what regulators expect early, and how smart interaction reduces risk and wasted effort. This episode helps founders understand how to engage FDA early and productively. Dr. Glass explains when to initiate regulatory conversations, what agencies are really looking for, and how early feedback can shape smarter development s...